Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

Cardio-TTRansform : A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18-90Age 18-90

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAmyloidosis

Trial Overview Read MoreRead more

This phase III trial is evaluating how effective 4-weekly injections of the drug Eplontersen, compared with a placebo, is in people with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM).
 

This trial is treating patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM).

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Commercial Sponsor

Ionis Pharmaceuticals, Inc.

Summary

This is a randomised, double blind trial evaluating the efficacy of eplontersen compared to placebo for 120 weeks in people with Transthyretin-Mediated Amyloid Cardiomyotherapy (ATTR-CM) receiving available standard of care (SoC). Participants will be randomly assigned to either the Experimental Arm or Placebo Comparator Arm. Participants in the Experimental Arm will receive eplontersen, administered via an injection, once every 4 weeks. Participants in the Placebo Comparator group will receive a placebo, administered via injection, once every 4 weeks. All participants will also receive daily supplemental doses of the recommended daily allowance of vitamin A.

Recruiting Hospitals Read MoreRead more

Box Hill Hospital, Malignant Haematology
Box Hill
Ms Liz Arnold
liz.arnold@monash.edu
03 9094 9516

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next